Effect of Dipyridamole on Spontaneous Platelet Aggregation in Whole Blood Decreases with the Time After Venepuncture: Evidence for the Role of ADP

Summary

Spontaneous platelet aggregation (SPA) was studied in human whole blood at 3, 5, 10, 20, 30, 40 and 60 minutes after venepuncture. Using a whole blood platelet counter, SPA was quantified by measuring the fall in single platelet count upon rollermixing aliquots of citrated blood at 37° C. The extent of SPA increased with the time after venepuncture, with a correlation coefficient of 0.819. The inhibitory effect of dipyridamole (Dipy) on SPA was studied: (a) 10 μM at each time interval; (b) 0.5-100 μM at 3 and 30 minutes and (c) 15 μM in combination with 100 μM adenosine, 8 μM 2-chloroadenosine (2ClAd, an ADP receptor blocker) and 50 μM aspirin. There was a rapid decrease in the inhibitory effect of Dipy with the time after venepuncture; the correlation coefficient was -0.533. At all the concentrations studied, Dipy was more effective at 3 minutes than at 30 minutes after venepuncture. A combination of Dipy with adenosine, 2ClAd or aspirin was a more effective inhibitor of SPA than either drug alone. However, when 15 μM Dipy and 10 μM Ad were added together, the inhibitory effect of Dipy was not increased significantly, suggesting that Dipy inhibits platelet aggregation independent of Ad. The increase in SPA with the time after venepuncture was abolished when blood was taken directly into the anticoagulant containing 5 μM 2ClAd. It is suggested that ADP released from the red blood cells is responsible for the increased platelet aggregability with the time after venepuncture and makes a serious contribution to the artifacts of in vitro platelet function studies.

Keywords

Time after venepuncture - Spontaneous platelet aggregation - Dipyridamole - 2-chloroadenosine - ADP

• References

• 1 Weiss HJ. Dipyridamole and other phosphodiesterase inhibitors. In Platelets Pathophysiology and Antiplatelet Drug Therapy. Harvey JWeiss. (Ed), pp 57-62 Alan R Liss Inc; New York: 1982
• 2 Harker LA, Kadatz RA. Mechanisms of action of dipyridamole. Thromb Res 1983; Suppl IV 39-46
• 3 Gresele P, Zoja C, Deckmyn H, Amout J, Vermylen J, Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemostas 1983; 50: 852-856
• 4 Kincaird-Smith P. Modification of vascular lesions of rejections in cadaveric renal allografts by dipyridamole and anticoagulants. Lancet 1969; 2: 920-922
• 5 Harker LA, Slinchter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-1305
• 6 Sullivan JM, Harken DW, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac valve replacement. N Engl J Med 1971; 284: 1391-1394
• 7 Persantin-aspirin Reinfarction Study Research Group Persantin and aspirin in coronary heart disease. Circulation 1980; 62: 449-461
• 8 Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, Frye RL, Holmes DR, Vliestra RE, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Schaff HV, Danielson GK. A platelet inhibitory drug trial in coronary artery bypass operations: benefit of preoperative dipyridamole and aspirin therapy on early postoperative vein graft patency. N engl J Med 1982; 307: 73-78
• 9 Chesebro JH, Fuster V, Elveback LD, Elveback LR, Clements IP, Smith HC, Holmes DR, Bardsley WT, Pluth JR, Wallace RB, Puga JF, Orszulak TA, Piehler JM, Danielson GK, Schaff HV, Frye RL. Effect of dipyridamole and aspirin on late vein graft patency after coronary bypass operations. N Engl J Med 1984; 310: 209-214
• 10 Best LC, McGuire MB, Jones P BB, Holand TK, Marti J, Preston FE, Segat DS, Russell R GG. Mode of action of dipyridamole on human platelets. Thromb Res 1979; 16: 367-379
• 11 Smith JB, Mills D CB. Inhibition of adenosine 3’-5’-cyclic monophosphate diesterase. Biochem J 1970; 120: 20p
• 12 Rozenberg MC, Walker CM. The effect of pyrimidine compounds on the potentiation of adenosine inhibition of aggregation, on adenosine phosphorylation and phosphodiesterase activity of blood platelets. Br J Haematol 1973; 24: 409-418
• 13 Emmons PR, Harrison M GJ, Honour AJ, Mitchell J RA. Effect of pyrimidopyrimidine derivative on thrombus formation in the rabbit. Nature 1965; 208: 255-257
• 14 Harker LA, Hanson SR. Experimental arterial thromboembolism in baboons: mechanisms, quantitation and pharmacological prevention. J Clin Invest 1979; 64: 559-569
• 15 Born G VR. Quantitative investigation into the aggregation of blood platelets. J Physiol 1962; 67-68
• 16 Harrison M GJ, Pollock SS, Steiner M, Weisblatt E. Inhibitors of spontaneous platelet aggregation in whole blood. Atherosclerosis 1985; 58: 199-203
• 17 Heptinstal S, Fox S, Crawford J, Hawkins M. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin. Thromb Res 1986; 42: 215-223
• 18 Santos MT, Aznar J, Valles J, Perez-Requejo JL. Evaluation in whole blood of antiplatelet activity of dipyridamole and pentoxifylline with the basic wave. Thromb Res 1986; Suppl IV: Abstr 296
• 19 Saniabadi AR, Lowe G DO, Barbenel JC, Forbes CD. A comparison of spontaneous platelet aggregation in whole blood with platelet rich plasma: additional evidence for the role of ADP. Thromb Haemostas 1984; 51: 115-118
• 20 Saniabadi AR, Lowe G DO, Barbenel JC, Forbes CD. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38: 225-232
• 21 Haslam RJ, Lynham JA. Activation and inhibition of blood platelet adenylate cyclase by adenosine and 2-chloroadenosine. Life Sci 1972; 11: 1143-1154
• 22 Premont J, Preez M, Bockaert J. Adenosine-sensitive adenylate cyclase in rate striatal homogenates (Letter). FEBS 1977; 75: 209-212
• 23 Nachman RL, Ferris B. Binding of adenosine diphosphate by isolated membranes from human platelets. J Biol Chem 1974; 249: 704-710
• 24 Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
• 25 Born G VR. Arterial thrombosis and its prevention. In: proceedings of the VIII World Congress of Cardiology. Shoji H, Satoru M. (Eds) pp 81-91 Excerpta Medica; Amsterdam. Oxford: 1979
• 26 Aursnes I, Gjesdai K, Abildgaard U. Platelet aggregation by ADP from unsheared erythrocytes at physiological Ca⁺⁺ concentration. Br J Haematol 1981; 47: 149-152
• 27 Fox SC, Bergess-Wilson M, Heptinstal S, Mitchell J RA. Platelet aggregation in whole blood determined using the Ultra Flo 100 platelet counter. Thromb Haemostas 1983; 48: 327-329
• 28 Saniabadi AR, Lowe G DO, Belch J JF, Forbes CD, Prentice C RM, Barbenel JC. The novel effects of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood. Thromb Haemostas 1983; 50: 718-721
• 29 Saniabadi AR, Lowe G DO, Belch J JF, Barbenel JC, Forbes CD. Effect of prostacyclin (Epoprostenol) on the aggregation of human platelets in whole blood in vitro. Haemostasis 1984; 14: 487-494
• 30 Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; 1: 1286-1289
• 31 Steer ML, MacIntyre DE, Levine L, Salzman EW. Is prostacyclin a physiologically important circulating antiplatelet agent. Nature 1980; 283: 194-195
• 32 Terres W, Becker BF, Kratzer M AA, Gerlach E. Increased platelet aggregability after venepuncture is platelet not plasma derived. Thromb Res 1986; 539-548
• 33 Gryglewski RJ. Prostacyclin and atherosclerosis. Trend Pharmacol Sci 1980; 2: 164-166